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Abstract 10 
This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly 11 
into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors 12 
regulating the degradation of 53 selected pharmaceuticals. Treated effluents from Bordeaux city 13 
(France) were mixed with water from the estuarine Garonne River during 4 weeks under 6 characterized 14 
conditions in order to assess the influence of suspended particulates, sterilization, untreated wastewater 15 
input and dilution on the degradation kinetics. Of the 53 pharmaceuticals monitored, 43 were quantified 16 
at the initial time. Only 7 exhibited a persistent behavior (e.g. carbamazepine, meprobamate) while biotic 17 
degradation was shown to be the main attenuation process for 38 molecules (e.g. abacavir, ibuprofen 18 
highly degradable). Degradation was significantly enhanced by increasing concentrations of suspended 19 
solids. A persistence index based on the half-lives of the compounds has been calculated for each of the 20 
43 pharmaceuticals to provide a practical estimate of their relative stability. The stability of 21 
pharmaceuticals in estuarine environments is likely to be highly variable and attenuated primarily by 22 
changes in suspended solid concentration. 23 
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Highlights: 28 
- Wastewater derived pharmaceuticals were incubated in estuarine waters 29 
- Dissolved and particulate concentrations were monitored over 4 weeks 30 
- Only 7/43 pharmaceuticals were persistent 31 
- Degradation rates were enhanced by increasing particle concentrations 32 
- Limited degradation in sterilized conditions 33 
 34 
 35 
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1 Introduction 36 
Since pharmaceuticals were identified as contaminants of emerging concern (Daughton and Ternes, 37 
1999), their occurrence in urban and natural aquatic systems has been increasingly studied. Multi-38 
residue screenings have confirmed their presence in wastewater (López-Serna et al., 2010; Rosal et al., 39 
2010), surface water (Baker and Kasprzyk-Hordern, 2013; Silva et al., 2011), seawater (Benotti and 40 
Brownawell, 2007; Vidal-Dorsch et al., 2012) and groundwater (Hass et al., 2012; Vulliet and Cren-41 
Olivé, 2011). 42 
After discharge into a water body, concentrations of pharmaceuticals in the dissolved phase are governed 43 
by physical processes such as dilution, diffusion and transport as well as by chemical (abiotic) or 44 
biochemical (biotic) processes. While the physical processes are likely to be similar between all 45 
contaminants, physico-chemical and biochemical processes will differ according to molecular structures 46 
(Fatta-Kassinos et al., 2011). In environmental waters, physico-chemical processes relate mainly to 47 
photodegradation and sorption. Photodegradation is well documented, with many studies for each 48 
carbamazepine, diclofenac, sulfamethoxazole and propranolol (Challis et al., 2014; Trawiński and 49 
Skibiński 2017). Concerning sorption to suspended solids (SS) and sediments, pharmaceuticals have 50 
received less attention owing to their perceived hydrophilic nature. However, historical records of 51 
pharmaceutical contamination have been recently detected in an urban impacted estuary (Lara-Martín 52 
et al., 2015) and some authors have reported significant partitioning to sediment of compounds such as 53 
psychotropics and β-blockers (Aminot et al., 2015; Baker and Kasprzyk-Hordern, 2011; Burke et al., 54 
2013). 55 
To date, most of the studies on pharmaceutical biodegradation focus on their fate through wastewater 56 
treatment and during biological secondary treatment (Lahti and Oikari, 2011; Pomiès et al., 2013). 57 
However, despite their continuous input to surface waters through treated urban effluents and/or 58 
combined sewers overflows (Verlicchi et. 2012), little is known of the parameters governing the fate of 59 
pharmaceuticals after discharge. Biodegradation can be investigated through in-stream studies 60 
(Aymerich et al., 2016; Kunkel and Radke, 2011; Writer et al., 2013) and laboratory experiments 61 
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(Baena-nogueras et al. 2017 ; Benotti and Brownawell, 2009; Bradley et al., 2007; Grenni et al., 2013; 62 
Yamamoto et al., 2009). Even if laboratory experiments do not strictly represent natural aquatic systems 63 
(Kunkel and Radke, 2011) they can provide important information concerning the factors governing in-64 
stream attenuation. Previous studies (Bradley et al., 2007; Radke and Maier, 2014) have evaluated the 65 
ability of river sediments to biodegrade pharmaceuticals. Other incubation experiments (Benotti and 66 
Brownawell, 2009) have revealed important differences in the biodegradation rates of studied 67 
compounds e.g. a paracetamol half-life of less than 1 day compared to a half-life of carbamazepine 68 
which is greater than 100 d. The authors also observed that in coastal waters kinetics of degradation 69 
were faster under eutrophic conditions. 70 
In this context, and as numerous cities like Bordeaux in France, are located along estuaries subject to 71 
tidal cycles, there is a real need to investigate the fate of pharmaceuticals in such environments (Zhao 72 
et al., 2015). Previous research evidenced a removal of some compounds within the Garonne estuary, 73 
with an increase of the attenuation rates in low flow summer periods (Aminot et al., 2016). Water 74 
dynamics in tidal estuaries are complex and a zone of high turbidity, known as the Turbidity Maximum 75 
Zone (TMZ), is generally observed at the freshwater/seawater interface. In this area, the number of 76 
freely suspended bacteria and their growth rate are small compared to those living on the particles 77 
(Plummer et al., 1987, Servais and Garnier, 2006), so the particles of the TMZ are expected to play a 78 
key role on the biochemical processes governing the water quality, in particular the organic contaminant 79 
concentration (Abril et al., 1999; Lanoux et al., 2013).  80 
Up to now, the transport and reactivity of emerging contaminants in estuarine environments are poorly 81 
understood, yet it closely relates to their effects in such coastal ecosystems. In particular, it remains 82 
unclear if the estuarine TMZ acts as a passive vector of contaminants from land to sea or as an active 83 
incubator, and, if so, whether sorption or biodegradation is the dominant transformation process. This 84 
study, therefore, aims to fill in an important gap in our knowledge by identifying in which way selected 85 
pharmaceuticals and estuarine particles characteristic of the TMZ interact. Laboratory batch 86 
experiments simulating mixing conditions of the discharge of wastewater into a turbid estuary were 87 
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performed to assess the influence of suspended solid concentration, type of effluent and dilution on a 88 
selection of 53 pharmaceuticals present in waste water from the city of Bordeaux. 89 
2 Experimental methods 90 
2.1 Estuarine river water and waste water characteristics 91 
River water (approx. 100 L) was collected in 20 L HDPE (High Density PolyEthylene) flasks from the 92 
estuarine Garonne River adjacent to the city of Bègles (coordinates 44°47'58.31"N; 0°31'37.99"W). This 93 
hydrosystem is a macrotidal estuary characterized by a tidal cycle dependent TMZ (Lanoux et al., 2013). 94 
Water was sampled at mid-ebb to ensure the highest SS concentration. Three 20 L flasks were subject 95 
to magnetic stirring to prevent particle settlement whilst two others were left unagitated for three days 96 
at room temperature in the dark. This treatment provided samples from the same water body under three 97 
different suspended solid conditions: unagitated flask supernatants, stirred waters and unagitated flask 98 
concentrates from the settled particles at respectively low (0.1 g.L-1), intermediate (1 g.L-1) and high 99 
(10 g.L-1) SS concentration. Water salinity was representative of TMZ particularity (0.5 ‰) (Lanoux et 100 
al. 2013). 101 
A few hours before the start of the experiment, large volume wastewater grab samples (approx. 80 L 102 
effluent and 20 L influent) were collected in 20 L HDPE flasks from one of the two major waste water 103 
treatment plants (WWTP) of the Bordeaux urban area in October 2012 (Clos de Hilde WWTP). This 104 
WWTP served 264 600 inhabitants (estimate of Lyonnaise des Eaux, manager). The WWTP is equipped 105 
with biofilters as a secondary treatment.  106 
2.2 Chemicals and selection of 53 pharmaceuticals 107 
Fifty-three commonly used pharmaceuticals were chosen using multistep selection based upon sales 108 
statistics, occurrence and fate in aquatic environment. Selected pharmaceuticals belong to various 109 
therapeutic classes and physicochemical properties and were quantified in the studied wastewater 110 
effluent in preliminary studies. Details on pharmaceuticals and chemicals used are given elsewhere and 111 
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in Table I (Aminot et al., 2015). Mercury (II) chloride (99 %) was purchased from Sigma-Aldrich (Saint 112 
Quentin Fallavier, France). 113 
2.3 Incubation experiment set-up 114 
Incubation experiments were adapted from previous works on the characterization of organic matter 115 
degradation in TMZ (Lanoux, PhD, 2013). 116 
Cubic 30 L glass aquariums were filled with river water and wastewater under the 6 following conditions 117 
(Figure 1): low SS (LSS) 12.5 L effluent, 12.5 L river water supernatant; intermediate SS (MSS) 12.5 L 118 
effluent, 12.5 L stirred river water; high SS (HSS) 12.5 L effluent, 12.5 L river water concentrate; 119 
untreated wastewater (Unt) 12.5 L influent, 12.5 L stirred river water; sterilized condition (HgCl2) 120 
12.5 L effluent, 12.5 L stirred river water, mercury (II) chloride at 100 mg.L-1; higher dilution (10xD) 121 
2.5 L effluent, 22.5 L stirred river water. 122 
Continuous mixing was performed by homemade glass rotors mounted on overhead stirrers while air 123 
was bubbled in through immersed frits at an approximate 1 L.min-1 rate. The 6 experimental devices 124 
remained in an air-conditioned room (room temperature varied between 18 and 22.5 °C) in the dark. 125 
The ambient pharmaceutical concentrations in wastewater effluent samples mixed with estuarine water 126 
were sufficient that additional spiking was not required (no introduction of carrying solvent). The 127 
dilution rates were chosen as a compromise of environmental relevant levels and to ensure the detection 128 
of the analytes on their whole degradation kinetics. Tenfold wastewater dilution (10xD) is comparable 129 
to an effluent discharge into a small river. To compensate for this higher dilution, 7 selected compounds 130 
(abacavir, carbamazepine, fenofibric acid, ibuprofen, naproxen, paracetamol, sotalol) were spiked into 131 
this aquarium to achieve a target concentration of 500 ng.L-1 (Figure 1).  132 
Poisoning with mercury (II) chloride has already been used efficiently for soil sterilization prior to PAH 133 
analysis (Wang et al., 2011), pharmaceuticals analysis (Yu et al. 2006) and nutrient analysis (Fitzhugh 134 
et al., 2003; Wolf et al., 1989) as well as for nutrient analyse of marine waters (Kattner, 1999). Regarding 135 
waste waters, it was observed that complete inhibition of microbiological growth was achieved when 136 
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preserved with 40 mg.L-1 of mercuric chloride, provided that total organic carbon (TOC) was below 20 137 
mg.L-1 (Krawczyk, 1975). With average levels of TOC in the effluent of 21.5 mg.L-1 (Lanoux, 2013) 138 
and of 5.7 mg.L-1 (Abril et al., 2002) in the estuarine waters, the chosen HgCl2 level of 100 mg.L-1 is 139 
adequate.  140 
2.4 Sampling and analysis 141 
Sampling was performed 10 min after water mixing (T0) and after 7, 14, 21 and 28 days in parallel with 142 
conductivity, pH, dissolved O2 (percentage) and water temperature measurements (note that the 143 
sterilized condition was not monitored to prevent probe damage and cross-contamination). Water 144 
samples were filtered through glass microfiber filters, GF/F (0.7 μm) (Whatman, supplied by Fisher 145 
Bioblock Scientific, Illkirch, France), 4 filters were kept for particle analysis and samples were stored 146 
at -20 °C.  147 
Water samples were extracted in triplicate by Solid Phase Extraction (SPE) and filters of suspended 148 
solids by focused microwave assisted extraction (MAE). Analysis was performed by LC-MS/MS. 149 
Protocol details and performance can be found in a previous work (Aminot et al., 2015). Briefly, accurate 150 
quantification was ensured by the use of 32 labeled internal standards (given in Table I), spiked in the 151 
samples prior to extraction. One processed spiked sample and one procedural blank sample were 152 
included in each batch of 12 samples (18 control points for waters and 6 for particles). The LC-MS/MS 153 
injections were conducted in one batch, with instrumental calibrants injected every 20 injections and 154 
instrumental blanks in between triplicates. Procedural and instrumental blanks revealed no 155 
contamination during sample preparation and analysis. By using numerous internal standards 156 
compensating for potential preparation losses and matrix effect, the procedural recoveries were in an 157 
acceptable range of 80–120 % for 47 (SPE) and 45 (MAE) of the studied compounds (the compounds 158 
with lower recoveries were 4-chlorobenzoic acid, ranitidine, losartan, salbutamol, terbutaline for SPE 159 
and MAE, plus indinavir for SPE, and lamivudine, caffeine and disopyramide for MAE). Limits of 160 
detection did not exceed 1 ng.L-1 for 40 compounds (6 ng.L-1 for the 13 remaining). 161 
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2.5 Physico-chemical parameters 162 
The evolution of conductivity, salinity, pH and dissolved oxygen during the 4-week incubation is 163 
presented in Figure S1. Initial conductivity was around 1200 µS.cm-1 in conditions LSS, MSS, HSS and 164 
Unt (50:50 dilution rate) and reached 1300 µS.cm-1 in condition 10xD due to the higher brackish water 165 
content. In the 5 monitored conditions, conductivity showed a progressive 5 to 10 % increase every 166 
week. This increase was attributed to a slight evaporation of the water in the air-conditioned laboratory. 167 
This was also reflected with persistent contaminants like carbamazepine, as detailed further in 3.2. pH 168 
values ranged between 7.8 and 8.8 with similar tendencies among the experimental conditions: an initial 169 
2-week decrease followed by a 2-week increase, probably in association with the assumed evaporation. 170 
Rapid ammonia oxidation can be accountable for the initial pH decrease. Except after water mixing 171 
(T0), dissolved oxygen was close to 100 %, indicating that the air-bubbling was adequate to maintain 172 
aerobic conditions. SS initial concentrations and relative changes during the experiment are available in 173 
Table S1, S2 and Figure S2. Tested SS concentrations varied between conditions by a factor of 50 from 174 
0.08 to 4 g.L-1 which are environmentally relevant levels in estuarine waters. After an initial decrease 175 
related to the observable sedimentation, this parameter followed the global increase trend attributed to 176 
evaporation. 177 
2.6 Data analysis  178 
2.6.1 Normalization of pharmaceutical concentrations 179 
The slight evaporation over the 4 weeks of incubation caused a concentration increase. Considering 180 
carbamazepine’s high stability (Benotti and Brownawell, 2009; Chenxi et al., 2008; Kunkel and Radke, 181 
2012) and its good analytical robustness (Aminot et al., 2015), other analytes were normalized to 182 
carbamazepine concentration in each treatment and sampling time (with carbamazepine concentration 183 
set constant at 100 %). The concentrations of carbamazepine with no adjustment are given in Figure S3.  184 
2.6.2 Half-lives and persistence indices 185 
Half-lives were extrapolated from the experimental data (Table 2) by linear regression (detailed in 186 
supporting information “half-life calculation”). The application of a finer model would have required 187 
additional sampling points in the vicinity of the lag phase and more complex mathematical tools (Chong, 188 
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2009), outside the scope of this study. Analytes showing a concentration higher than 80 % of the initial 189 
concentration after 4 weeks were considered as stable. Concerning compounds undetected after 1 week, 190 
calculation gives a 3.5 d half-life but the actual half-life can be somewhat shorter. 191 
In order to give a practical relative comparison of the compound degradabilities (including abiotic), a 192 
persistence index based on the compound half-lives was calculated. It consists of grading each 193 
pharmaceutical in each treatment where it was quantified. Marks depend on half-life values: < 7 d = 0; 194 
from 7 to 14 d = 20; from 14 to 21 d = 40; from 21 to 28 d = 60; > 28 d = 80; not calculable because of 195 
stable concentrations = 100. The average mark gives the persistence index (Table 2). 196 
3 Results and discussion 197 
Concentrations are given as total, i.e. the sum of SS- and dissolved-phase concentrations (measured 198 
separately). Of the 53 monitored analytes, 43 were quantified after initial water mixing (T0) in at least 199 
one treatment and 26 in the 6 treatments (Table S3). 200 
3.1 Behavior of the pharmaceuticals  201 
3.1.1 Impact of sterilization 202 
To evaluate if mercury (II) chloride poisoning affected the analytes, initial concentrations in the 203 
sterilized condition were compared to the average concentrations in conditions LSS, MSS and HSS which 204 
are similar in terms of effluent type and dilution. Agreement between these conditions, plotted in Figure 205 
S4, indicates that out of the 40 molecules quantified above their limit of quantification (equal to 3.3 206 
times the limit of detection) in conditions LSS, MSS and HSS, 26 were considered unaffected by HgCl2, 207 
while 8 were partially affected (CHgCl2 < 0.8*CLSS,MSS,HSS for lamivudine, ritonavir, alprazolam, 4-208 
chlorobenzoic acid, primidone, theophylline, losartan, disopyramide) and 6 were highly affected 209 
(CHgCl2 < 0.2*CLSS, MSS, HSS for abacavir, bromazepam, atorvastatin, ranitidine, salbutamol). Appropriate 210 
responses for the internal standards (abacavir d4, bromazepam d4, atorvastatin d5, primidone d5) 211 
preclude any analytical artefacts. These losses were rapid for some compounds (e.g. abacavir) with the 212 
analytes not being detected a few minutes after water mixing at T0. This sterilization method has 213 
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previously been applied without significantly altering the organic matter of soils (Fitzhugh et al., 2003; 214 
Wolf et al., 1989). However, a 2-36 % loss of PAH has already been observed following mud 215 
sterilization (Wang et al., 2011). HgCl2 has also been shown to be capable of rapidly degrading the 216 
booster biocide Irgarol 1051 at environmental pH by hydrolysis of the cyclopropylamine group (Liu et 217 
al., 1999). Hydrolysis of abacavir, with a similar functional group, could account for its disappearance, 218 
although further investigations are required to evaluate the mechanism. 219 
Focusing only on the 26 unaffected analytes, the conditionHgCl2 can be considered as an abiotic batch 220 
control experiment. Steady concentrations were observed for 13 pharmaceuticals (lamuvidine, 221 
ketoprofen, naproxen, ibuprofene, hydroxy-ibuprofene, gemfibrozil, bezafibrate, 4-chlorobenzoic acid, 222 
fenofibric acid, pravastatin, metoprolol, sotalol, losartan) over the 21 days of incubation in this condition 223 
only (all data supplied in the Supporting Information, Figure S5). 224 
3.1.2 Degradation and the influence of suspended solids 225 
Considering conditions LSS, MSS, HSS and the sterilized condition HgCl2, 4 specific behaviors were 226 
noticeable (Figure 2, all data are plotted in Figure S5). The meprobamate-type compounds (Figure 2.a) 227 
exhibited constant concentrations (> 80 % T0) in all conditions over the 4 weeks (bromazepam, 228 
nordiazepam, alprazolam, lorazepam, meprobamate, primidone, and carbamazepine). The bezafibrate-229 
type compounds (Figure 2.b) showed constant concentrations in the sterilized condition but decreasing 230 
concentrations under the biotic conditions with faster kinetics observed for higher SS concentrations 231 
(ketoprofen, naproxen, diclofenac, ibuprofene, hydroxy-ibuprofene, gemfibrozil, bezafibrate, 4-232 
chlorobenzoic acid, fenofibric acid, pravastatin, metoprolol, sotalol, cetirizine, losartan, disopyramide). 233 
The atenolol-type (Figure 2.c) concentration decrease was more rapid than for the bezafibrate-type and 234 
included some degradation under sterilized conditions (lamivudine, zidovudine, atenolol, bisoprolol, 235 
propranolol, caffeine, theophylline, abacavir, acebutolol, ranitidine). The ritonavir-type compounds 236 
(Figure 2.d) exhibited rapid decreasing concentrations in all the conditions with similar kinetics between 237 
sterilized and biotic conditions (ritonavir, oxazepam, amitriptyline, fluoxetine, clopidogrel). All the non-238 
persistent molecules exhibited an initial slow concentration decrease (lag period) followed by an 239 
acceleration of the kinetics (Figure 2.b). 240 
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Suspended solids are known to play a crucial role in biogeochemical processes between water, sediments 241 
and microorganisms (Turner and Millward, 2002). The degradation observed was mainly biotic 242 
(bezafibrate- and atenolol-type) as the sterilized condition remained higher or even constant. Only for 243 
the 5 molecules in the ritonavir-type category the similarity between sterilized and biotic conditions 244 
implied abiotic processes as the major degradation pathway. An overall increase in the biodegradation 245 
rate was measured for increasing concentrations of SS. Bacterial activity is largely dominated by 246 
bacteria living on particles in estuarine waters: Plummer and co-workers (Plummer et al., 1987) 247 
measured a contribution of freely suspended bacteria as little as 15 % of the whole bacteria enumeration 248 
and activity in the Tamar TMZ (UK) while Servais and Garnier (2006) showed that the growth rates of 249 
attached bacteria were, on average, three times higher than those of free-living ones. Consequently, 250 
additional bacteria are brought with increasing SS concentrations and the biochemical processes are 251 
promoted, in agreement with our findings. This is also in agreement with the increased microbial 252 
respiration measured as the depletion of dissolved oxygen in the TMZ of the Gironde estuary, France 253 
(Lanoux et al., 2013). 254 
The observed kinetics is inconsistent with a first-order reaction, even though it was reported in previous 255 
studies (Li et al., 2015). The initial lag phase has also been identified during degradation by activated 256 
sludge of dissolved organic matter (Galvez et al., 1996), ibuprofen and ketoprofen (Almeida et al., 2013) 257 
as well as for bisphenol A, estradiol and ethinylestradiol degradation in the marine environment (Ying 258 
and Kookana, 2003). This evolution has been attributed to the acclimation and development of the 259 
microbial populations in general (Almeida et al., 2013; Chong, 2009; Ying and Kookana, 2003) and 260 
sigmoidal functions were previously proposed to model the kinetics. Biodegradation of amino acids in 261 
estuarine waters, in the absence of wastewater, also showed a delayed degradation after the initial 262 
compound spiking (Tappin et al., 2010). These studies and our observed kinetics suggest that a 263 
development and/or acclimation of the microbial populations occurred after mixing estuarine water with 264 
wastewaters. This supports the conclusions that the biodegradation was mainly the consequence of the 265 
degrading microbes from the turbid river water, un-acclimated yet to the wastewater born 266 
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pharmaceuticals, and not the consequence of the wastewater effluent microorganisms, as the wastewater 267 
dilution rate showed no influence on the kinetics. 268 
3.1.3 Influence of effluent treatment 269 
Comparing conditions MSS and Unt, respectively comprising a WWTP effluent and influent, affords 270 
consideration of both the type of effluent and the SS concentration/nature (Figure 3). Analytes exhibited 271 
slightly faster degradation under condition Unt, with half-lives a few days shorter (2.5 d and 10 d in the 272 
case of naproxen and zidovudine, respectively, Figure 3.a and b). Only in the case of fenofibric acid 273 
(Figure 3.c), a significantly slower degradation was observed with influent wastewater. Potentially high 274 
concentrations of fenofibrate (the unmonitored parent compound of fenofibric acid in human 275 
metabolism) in the influent could account for this result through degradation into fenofibric acid. 276 
However, studies on such a transformation have not been reported in literature. 277 
3.1.4 Influence of dilution rate 278 
Conditions MSS, HSS - composed of 50 % vol. effluent - and 10xD -composed of 10 % vol. effluent- 279 
were compared to explore the impact of dilution on the degradation kinetics. SS concentrations in 280 
condition 10xD were included between conditions MSS and HSS (Table S1). For all the degradable 281 
molecules in these 3 conditions, the kinetics was function of the SS concentration and no atypical 282 
behavior emerged from condition 10xD.  283 
3.2 Sorption of pharmaceutical to suspended solid  284 
The number of detected pharmaceuticals was dependent on the suspended solid concentration of the 285 
treatment considered. In condition MSS, with intermediate SS concentrations, up to 25 molecules were 286 
quantified on SS while 41 were found in dissolved phase. The evolution of the analyte concentrations 287 
on SS and in the dissolved phase were similar for all detected compounds (Figure S6). 288 
When comparing the experimental conditions LSS, MSS and HSS which were similar in terms of dilution 289 
rate and effluent type, the highest pharmaceutical concentrations on particles were observed for the 290 
lowest SS concentrations. It was found that the partition coefficient Kd decreased with SS concentration 291 
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with a difference up to 2 log between the lowest and highest SS conditions (Figure 4). This observation 292 
was not due to a change in organic content of SS as log Koc exhibited a similar trend. Average partition 293 
coefficients measured in the intermediate condition MSS are available in the supporting information for 294 
every pharmaceutical detected in both the dissolved and particulate phases at least twice in the 4 weeks 295 
(Table S4). Ritonavir, amitriptyline and propranolol have the highest affinity with SS, as previously 296 
observed (Aminot et al., 2015).  297 
The partitioning coefficients Kd and Koc, ranging from 0.6 to 3.7 and 0.5 to 3.0 respectively, in the 298 
intermediate SS concentration condition (MSS), were low to moderate (Table S4) and in agreement with 299 
previously reported values (Al-Khazrajy and Boxall, 2016; Aminot et al., 2015). Poor correlation 300 
(R2=0.07) was obtained when attempting to correlate log Kd with log D at pH 8 (Figure S7). As an 301 
example, beta-blockers, all containing one (propranolol, metoprolol, bisoprolol) to two (sotalol, 302 
acebutolol) secondary amines moieties and positively charged at pH 8 showed an affinity to SS 1 to 2 303 
orders of magnitude higher than diclofenac, fenofibric acid and bezafibrate, containing a carboxylic acid 304 
function and negatively charged at pH 8, despite a similar log D at pH 8. It was previously showed that 305 
compounds with basic characteristics, protonated under natural water pH, tend to show higher affinity 306 
to the negatively charged SS (Schaffer et al., 2012; Silva et al., 2011). Variabilities in the sorption of 307 
pharmaceuticals and other organic contaminants between different substrates are also attributed to 308 
factors like their organic carbon content and quality, mud/clay content or inorganic cation content 309 
(Aminot et al., 2015; Belles et al., 2016; Schaffer et al., 2012; Silva et al., 2011). Interestingly, the 310 
partitioning coefficients were found to be dependent on the SS concentration. Non-constant Kd indicate 311 
a non-linear adsorption isotherm, which could be better described by more complex adsorption models, 312 
outside the scope of this study. In our case, the type of particle is the same across experimental conditions 313 
and only its concentration varied. Similar behaviour was observed for carbamazepine, propranolol and 314 
diclofenac on SS in Kent River, UK (Zhou and Broodbank, 2014). The authors proposed a power law 315 
to describe decreasing Kd for increasing SS and attributed this observation to a combination of multiple 316 
factors including a higher sorbing power of fine and organic-rich SS at low SS concentrations, increasing 317 
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desorption at high SS concentrations due to more frequent interactions of SS, and potentially higher 318 
colloids being produced at high SS concentrations competing with SS. 319 
3.3 Half-lives and persistence indices and pharmaceutical degradability  320 
Half-lives as a function of SS concentrations (Figure 5) followed a decreasing exponential form. It 321 
indicates that a similar variation in SS concentrations will have a higher impact on the degradation 322 
kinetics at low SS values compared to high SS values. Between conditions 10xD and HSS, a 2-fold SS 323 
concentration increase has little effect on half-lives. Kinetics were different in condition Unt (influent 324 
wastewater) for losartan, gemfibrozil and bezafibrate, giving a point slightly aside of the exponential 325 
trend. 326 
In order to compare relative compounds degradabilities, a persistence index was calculated (Table 2). 327 
Of the 43 molecules, 6 (paracetamol, abacavir, ritonavir, saquinavir, atorvastatine, clopidogrel) were 328 
considered as very degradable with an average score of 0 whilst 8, all psycholeptics (bromazepam, 329 
nordiazepam, alprazolam, diazepam, lorazepam, meprobamate, primidone, carbamazepine), were very 330 
persistent (score 100). Oxazepam scored 80 but exhibited a very slight decrease with a half-life > 60 d. 331 
Up to 14 analytes (/43 detected) were considered as stable in biotic conditions (bromazepam, 332 
nordiazepam, alprazolam, lorazepam, meprobamate, primidone, carbamazepine, ranitidine, acebutolol, 333 
diclofenac, timolol, cetirizine, nevirapine and disopyramide in the “LSS” condition). Relative 334 
persistence is consistent with those reported in literature: e.g. naproxen < gemfibrozil (Grenni et al., 335 
2013); paracetamol << carbamazepine (Yamamoto et al., 2009); paracetamol < caffeine < ketoprofene 336 
< salbutamol ≈ ranitidine < carbamazepine (Benotti and Brownawell, 2009). The relative persistence 337 
and half-lives values calculated in the highest SS condition (HSS) are in agreement with those calculated 338 
at the water sediment interface in a previous study (Li et al., 2015). Psycholeptics compounds like 339 
benzodiazepines showed minor to no degradation. Diazepam was found to be refractory in the absence 340 
of sunlight in a previous incubation of estuarine waters (Tappin et al., 2014). Oxazepam persistence in 341 
estuarine conditions is consistent with its stability through wastewater treatment (González Alonso et 342 
al., 2010; Yuan et al., 2013) and in fresh waters (Hass et al., 2012). Our findings emphasize the concerns 343 
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on this pharmaceutical, recently reported as bioaccumulative (Lagesson et al., 2016) and toxic (Brodin 344 
et al., 2013). 345 
3.4 Implications on pharmaceutical degradability in estuaries 346 
Macrotidal estuaries are characterized by their TMZ in which river water and its organic contaminants 347 
from upstream meet high SS concentrations in the freshwater/surface water Interface. In the estuarine 348 
Garonne River, the SS concentration close to the discharge point of Bordeaux city effluents has seasonal 349 
variations from less than 50 mg.L-1 during high flows to over 10 g.L-1 during low flow periods (Etcheber 350 
et al., 2011). Additionally, intra-day variations are based on the tidal cycle with a maximum SS 351 
concentration reached at mid-ebb where a tenfold increase can be observed within 3 h. Considering the 352 
longitudinal transport of contaminants, when approaching the TMZ from upstream, contaminants are 353 
exposed to increasing SS concentrations whilst after the TMZ and along the salinity gradient, the SS 354 
concentration decreases. In agreement with the conclusions of our experiments, the rise in SS is expected 355 
to enhance the degradation rate of pharmaceuticals inducing high spatial and temporal variations on the 356 
compounds degradation rates. The seasonal removal of pharmaceuticals, previously demonstrated in the 357 
Garonne estuary (Aminot et al., 2016), is likely not only to be due to increased water residence time but, 358 
also a consequence of more turbid waters during the low flow summer period. A recent study also 359 
observed that river waters could show higher attenuation efficiencies than WWTPs for a same residence 360 
time, confirming that environmental degradation processes are significant and not only controlled by 361 
residence time (Aymerich et al., 2016).  362 
When taking into account the numerous water physicochemical parameters that may influence 363 
degradation, the understanding of the processes governing in-stream attenuation becomes excessively 364 
complex and in-vitro experimentation is necessary. Besides, additional work on the microbial fauna is 365 
required to understand the degrading power of the different bacterial communities that may be associated 366 
with freshwater, TMZ and marine waters. In addition to SS, it has been shown that pharmaceuticals tend 367 
to degrade faster in more eutrophic waters, or waters more concentrated in biodegradable dissolved 368 
organic carbon (Benotti and Brownawell, 2009; Lim et al., 2008). Our degradation experiments have 369 
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been conducted under aerobic conditions. Previous studies (Ying and Kookana, 2003) demonstrated that 370 
the stability of organic micropollutants (steroids, alkylphenols, bisphenol A) in seawater was 371 
significantly increased under anaerobic conditions. Similarly, enhancement in biodegradation rates was 372 
observed after introducing oxygen to an anoxic water/sediment system (Radke and Maier, 2014). In the 373 
estuarine Garonne River, dissolved oxygen can reach 30 % at 1 m under the surface in summertime 374 
(Lanoux et al., 2013) while anoxic conditions have been observed in the fluid mud (SS concentrations 375 
> 140 g.L-1) (Abril et al., 1999). Persistence of the contaminants is then expected to be enhanced under 376 
such conditions. 377 
4 Conclusions 378 
The quantification of 43 of the 53 screened pharmaceuticals enabled the evaluation of their stability. 379 
Persistent behaviour was observed for 7 molecules during the 4 weeks of experiment, as indicated by 380 
the persistence index proposed (bromazepam, nordiazepam, alprazolam, diazepam, lorazepam, 381 
meprobamate, primidone, carbamazepine). By quantifying the analytes in the dissolved and particulate 382 
phases and comparing total concentrations to a sterilized condition, we provided evidence that biotic 383 
degradation and not sorption to particles was the main attenuation process. This biodegradation was 384 
enhanced by increasing concentrations of SS: half-lives were reduced by up to 6-fold by a 50-fold SS 385 
increase. The influence of the type of effluent as well as its mixing proportion appeared to be minor. 386 
When considering dissolved and particulate phases separately, it was found that the equilibrium between 387 
these compartments was a function of the SS concentration, although most of the targeted analytes 388 
exhibited low to moderate affinity towards particles, as per the low log Kd calculated. 389 
In natural aquatic systems and in particular in estuaries where the penetration of light is limited by the 390 
turbidity of the waters, biodegradation is expected to be a major removal process for pharmaceuticals. 391 
However, the kinetics of this attenuation is water body-dependent and its moderation by different 392 
bacterial communities or by variations in organic carbon particle compositions, in salinities, in oxygen 393 
rates etc. can be significant and requires further investigations. 394 
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Table I. Selected physicochemical properties of the studied pharmaceuticals, CAS number, associated 404 
internal standard. The partitioning coefficient log Kow, log D ph 2 and log D pH 8 were calculated using 405 
Chemaxon log D predictor tool (https://disco.chemaxon.com/apps/demos/logd). *pKa values were 406 
summarized by Shalaeva et al. 2007; Takayanagi et al. 2015; Barbic et al. 2007; Escher et al. 2010; 407 



















abacavir Antiretroviral 136470-78-5 286.33 0.39 -1.58 0.38 15.41/5.77 abacavir d4 ESI pos 
indinavir Antiretroviral 150378-17-9 613.79 2.81 -1.56 2.79 13.19/7.37 indinavir d6 ESI pos 
lamivudine Antiretroviral 134678-17-4 229.26 -1.1 -1.1 -1.1 14.29 lamivudine 15N2-13C ESI pos 
nelfinavir Antiretroviral 159989-64-7 567.78 4.72 1.46 4.52 9.32/8.18 nevirapine d3 ESI pos 
nevirapine Antiretroviral 129618-40-2 266.30 2.49 0.11 2.49 10.37/5.06 nevirapine d3 ESI pos 
ritonavir Antiretroviral 155213-67-5 720.94 5.22 4.49 5.22 13.68/2.84 nevirapine d3 ESI pos 
saquinavir Antiretroviral 127779-20-8 670.84 2.58 -0.36 2.56 5.11/8.31 nevirapine d3 ESI pos 
zidovudine Antiretroviral 30516-87-1 267.24 -0.3 -0.41 -0.42 9.96 zidovudine d3 ESI neg 
bromazepam Psycholeptic 1812-30-2 316.15 2.54 1.85 2.54 12.24/2.68 bromazepam d4 ESI pos 
nordiazepam Psycholeptic 1088-11-5 270.71 1.32 2.31 3.21 - nordiazepam d5 ESI pos 
alprazolam Psycholeptic 28981-97-7 308.77 2.37 -0.79 3.02 18.3/5.08 diazepam d5 ESI pos 
diazepam Psycholeptic 439-14-5 284.74 3.08 2.11 3.08 2.92 diazepam d5 ESI pos 
oxazepam Psycholeptic 35295-88-6 286.71 2.92 2.92 2.92 10.61/-1.5 oxazepam d5 ESI pos 
lorazepam Psycholeptic 846-49-1 321.16 3.53 3.53 3.53 10.61/-2.2 diazepam d5 ESI pos 
clonazepam Psycholeptic 106955-87-7 315.71 3.15 2.92 3.15 11.89/1.86 diazepam d5 ESI pos 
meprobamate Psycholeptic 57-53-4 218.25 0.93 0.93 0.93 15.17 meprobamate d3 ESI pos 
ketoprofen Analgesic 172964-50-0 254.28 3.61 3.61 0.18 3.88/-7.5 ketoprofen d3 ESI neg 
naproxen Analgesic 23981-80-8 230.26 2.99 2.98 -0.36 4.19/-4.8 naproxen d3 ESI neg 
diclofenac Analgesic 15307-86-5 296.15 4.26 4.25 0.85 4/-2.1 diclofenac d4 ESI neg 
ibuprofen Analgesic 58560-75-1 206.28 3.84 3.84 0.85 4.85 ibuprofen d3 ESI neg 
2-hydroxy-ibuprofen Analgesic 51146-55-5 222.28 2.37 2.37 -0.77 - OH ibuprofen d6 ESI neg 
paracetamol Analgesic 2248282 151.16 0.91 0.91 0.89 9.46/ paracetamol d4 ESI pos 
gemfibrozil Lipopenics 25812-30-0 250.33 4.39 4.39 1.14 4.42/-4.8 gemfibrozil d6 ESI neg 
bezafibrate Lipopenics 41859-67-0 361.82 3.99 3.98 0.55 3.83/-0.84 bezafibrate d6 ESI pos 
4-chlorobenzoic acid Lipopenics 74-11-3 156.57 2.23 2.23 -1.15 - diclofenac d4 ESI neg 
fenofibric acid Lipopenics 42017-89-0 318.75 4.36 4.33 0.85 -4.9 fenofibric acid d6 ESI neg 
clofibric acid Lipopenics 882-09-7 214.65 2.9 2.88 -0.6 0 clofibric acid d4 ESI neg 
pravastatin Lipopenics 81093-37-0 424.53 1.65 1.64 -1.69 4.21/ pravastatin d3 ESI neg 
atorvastatin Lipopenics 134523-00-5 558.64 5.39 5.39 2.09 4.33/-2.7 atorvastatin d5 ESI neg 
atenolol β-blocker 60966-51-0 266.34 0.43 -2.82 -1.24 14.8/9.67 atenolol d7 ESI pos 
bisoprolol β-blocker 66722-44-9 325.443 2.2 -1.05 0.53 14.09/9.67 propranolol d7 ESI pos 
metoprolol β-blocker 37350-58-6 267.36 1.76 -1.48 0.09 14.09/9.67 propranolol d7 ESI pos 
propranolol β-blocker 13013-17-7 259.34 2.58 -0.66 0.92 14.09/9.67 propranolol d7 ESI pos 
sotalol β-blocker 27948-47-6 272.36 -0.4 -3.19 -1.56 10.07/9.43 sotalol d7 ESI pos 
timolol β-blocker 131628-37-0 316.42 1.34 -1.91 -0.42 14.08/9.76 propranolol d7 ESI pos 
acebutolol β-blocker 37517-30-9 336.43 1.53 -1.71 -0.03 13.91/9.57 propranolol d7 ESI pos 
imipramine Antidepressant 50-49-7 280.41 4.28 0.77 3.06 9.2 amitriptyline d6 ESI pos 
doxepin Antidepressant 1668-19-5 279.38 3.84 0.34 2.08 9.76 amitriptyline d6 ESI pos 
amitriptyline Antidepressant 50-48-6 277.40 4.81 1.31 3.05 9.76 amitriptyline d6 ESI pos 
fluoxetine Antidepressant 57226-07-0 309.33 4.17 0.93 2.38 9.8 fluoxetine d5 ESI pos 
primidone Anticonvulsant 125-33-7 218.25 1.12 1.12 1.12 11.5/ primidone d5 ESI pos 
carbamazepine Anticonvulsant 298-46-4 236.27 2.77 2.77 2.77 15.96 carbamazepine d10 ESI pos 
cetirizine Antihistaminic 83881-51-0 388.89 0.86 -0.24 0.4 3.6/7.79 cetirizine d8 ESI pos 
ranitidine Antihistaminic 66357-35-5 314.40 0.98 -3.6 0.78 8.08 diazepam d5 ESI pos 
clenbuterol β2 agonist 37148-27-9 277.19 2.33 -1 0.71 14.06/9.63 diazepam d5 ESI pos 
caffeine Stimulant 71701-02-5 194.19 -0.55 -0.55 -0.55 - caffeine d9 ESI pos 
theophylline Bronchodilatator 58-55-9 180.16 -0.77 -0.77 -1.11 7.82 caffeine d9 ESI pos 
sildenafil PDE-5-inhibitor 139755-83-2 474.58 1.35 -1.51 0.92 7.27/5.97 sildenafil d3 ESI pos 
losartan Antihypertensive 114798-26-4 422.91 5.08 2.95 2.81 7.4/4.12 diazepam d5 ESI pos 
salbutamol Bronchodilatator 18559-94-9 239.31 0.34 -2.36 -0.77 10.12/9.4 diazepam d5 ESI pos 
clopidogrel Antiplatelet agent 113665-84-2 321.82 4.03 1.05 4.03 5.14 diazepam d5 ESI pos 
terbutaline Bronchodilatator 46719-29-3 225.28 0.44 -1.89 -0.19 8.86/9.76 diazepam d5 ESI pos 
disopyramide Antiarrythmics 3737-09-5 339.47 3.47 -0.73 1.08 16.19/10.42 diazepam d5 ESI pos 
 409 
 410 




Table II. Calculated half-lives (conditions sorted by increasing SS) and persistence indices. Average values ± 412 
uncertainties (n=3). Calculations are given in supplementary information. NC: not calculable as undetected. 413 
Analyte 
Half-lives (d) Persistence 
index LSS MSS Unt 10xD HSS HgCl2 
abacavir 3.6 ± 0.2 3.7 ± 0.5 3.6 ± 0.2 3.5 ± 0.4 3.5 ± 0.5 NC 0 
ritonavir 3.8 ± 0.4 3.8 ± 1 3.9 ± 0.4 3.7 ± 0.5 3.7 ± 1.1 5.7 ± 0.9 0 
saquinavir NC NC 4.1 ± 0.5 NC 3.5 ± 0.2 5 ± 0.8 0 
paracetamol NC NC 3.5 ± 0.2 3.5 ± 0.6 NC NC 0 
atorvastatin NC 3.5 ± 2.5 3.6 ± 3 NC NC NC 0 
clopidogrel 4.5 ± 1.2 5.5 ± 1.3 4.1 ± 0.4 4 ± 1 4.9 ± 1.2 4.5 ± 1.2 0 
caffeine 4.5 ± 0.7 3.8 ± 1.5 3.5 ± 0.2 3.9 ± 0.9 5 ± 0.7 39 ± 22 13 
theophylline 5.6 ± 1.1 5.2 ± 3.8 3.6 ± 0.1 4 ± 0.6 3.6 ± 2 31 ± 24 13 
lamivudine 3.5 ± 0.1 4.8 ± 0.5 5.2 ± 0.7 3.5 ± 0.4 3.5 ± 0.5 stable 17 
ibuprofen 6.5 ± 1 4.3 ± 0.4 3.5 ± 0.3 3.6 ± 0.2 3.5 ± 0.5 stable 17 
atenolol 5.6 ± 1 7.2 ± 1.3 5 ± 0.7 3.8 ± 0.8 3.7 ± 0.6 41 ± 37 17 
bisoprolol 13 ± 3 6.7 ± 1.2 4.7 ± 0.5 5.5 ± 1.3 4.9 ± 0.6 47 ± 57 17 
propranolol 6.9 ± 1.2 7.6 ± 1.6 5.2 ± 0.5 6.2 ± 1.3 4.9 ± 0.6 56 ± 139 17 
hydroxy-ibuprofen 9.5 ± 0.3 6.2 ± 0.5 3.5 ± 0.2 5.1 ± 1.4 4.9 ± 0.4 stable 20 
amitriptyline 4 ± 0.9 6.3 ± 2.1 steady at 55% NC 10.4 ± 2.6 3.9 ± 0.6 20 
ketoprofen 8.1 ± 0.4 6.1 ± 0.9 9.4 ± 1.4 6.8 ± 2.6 6.1 ± 0.5 stable 23 
fluoxetine 3.6 ± 0.4 6.3 ± 1 8.1 ± 4.8 NC stable 5.7 ± 1 24 
naproxen 16 ± 1 7.9 ± 0.7 5.4 ± 0.7 3.6 ± 0.4 3.5 ± 0.2 stable 27 
pravastatin 19 ± 4 7.7 ± 1.4 3.5 ± 0.3 3.5 ± 0.1 3.6 ± 0.3 stable 27 
fenofibric ac. 10 ± 0 8.7 ± 0.4 14 ± 1 5.5 ± 0.8 5 ± 0.6 stable 30 
metoprolol 24 ± 47 7.6 ± 1.6 5.5 ± 0.9 7.4 ± 0.2 5.2 ± 0.4 stable 33 
gemfibrozil 19 ± 3 13 ± 2 18 ± 3 11 ± 4 10 ± 1 stable 40 
bezafibrate 22 ± 3 14 ± 2 8.7 ± 1.3 11 ± 2 9.2 ± 0.8 stable 40 
4-chlorobenzoic ac. 17 ± 13 9.8 ± 0.9 NC NC 3.5 ± 0.3 stable 40 
ranitidine stable 12 ± 14 13 ± 5 NC 8.4 ± 4.9 NC 40 
salbutamol 33 ± 35 8.9 ± 2.2 NC NC 8.5 ± 3.5 NC 40 
sotalol steady at 60% 14.2 ± 3.1 12.9 ± 9.6 10 ± 2 4.9 ± 0.6 stable 43 
losartan 28 ± 7 17 ± 2 19 ± 5 10 ± 2 8.7 ± 0.8 stable 47 
acebutolol stable 18 ± 6 19 ± 7 26 ± 22 11 ± 3 NC 52 
zidovudine 49 ± 223 24 ± 10 14 ± 5 NC 8.2 ± 1.9 46 ± 137 56 
diclofenac stable 23 ± 2 14.6 ± 4.5 11.2 ± 2.2 8.9 ± 0.3 stable 57 
oxazepam 96 ± 38 97 ± 46 165 ± 228 72 ± 36 58 ± 23 65 ± 30 80 
timolol stable 30 ± 22 43 ± 45 NC 15 ± 13 stable 80 
cetirizine stable stable stable 37.1 ± 14.6 30 ± 18 stable 93 
nevirapine stable stable stable stable 30 ± 22 stable 96 
disopyramide stable stable stable stable 41 ± 167 stable 97 
bromazepam stable stable stable stable stable stable 100 
nordiazepam stable stable stable stable stable stable 100 
alprazolam stable stable NC NC NC NC 100 
diazepam NC NC stable stable NC stable 100 
lorazepam stable stable stable stable stable stable 100 
meprobamate stable stable stable stable stable stable 100 
primidone stable stable stable stable stable stable 100 
carbamazepine stable stable stable stable stable stable 100 
indinavir NC NC NC NC NC NC NC 
nelfinavir NC NC NC NC NC NC NC 
clonazepam NC NC NC NC NC NC NC 
clofibric ac. NC NC NC NC NC NC NC 
imipramine NC NC NC NC NC NC NC 
doxepine NC NC NC NC NC NC NC 
clenbuterol NC NC NC NC NC NC NC 
sildenafil NC NC NC NC NC NC NC 
terbutaline NC NC NC NC NC NC NC 
 414 





Figure 1. Experimental setup. 417 




Figure 2. Evolution of the relative concentrations for 4 molecules selected for the representativeness of the behaviours 419 
observed. LSS: low SS, MSS: intermediate SS, HSS: high SS, Unt: untreated waste water influent, HgCl2: abiotic 420 
reference, 10xD: higher WW dilution rate. The pie charts indicate the mass balance between the dissolved (grey) and 421 
particulate (black) phases in the condition MSS with intermediate particle concentration. Average values ± standard 422 
deviation (n=3). 423 
 424 




Figure 3. Changes in the relative concentrations under conditions MSS (treated effluent) and Unt (untreated effluent) 426 
during the degradation experiment for 3 selected-molecules. The mass balance between particulate (dark) and 427 
dissolved (clear) phases is given in the pie charts for the condition MSS at each sampling time. Details of the 428 
conditions are given in table 1. Average values ± standard deviation (n=3). 429 
 430 
Figure 4. Partition coefficient Kd and partition coefficient normalized by organic carbon content Koc for 3 selected 431 
analytes as a function of SS concentration in conditions LSS, MSS and HSS. Average values ± standard deviation, n=5 432 
(time points). 433 
 434 
 435 




Figure 5. Relationship between half-lives and SS concentration for 6 selected analytes in the biotic conditions. Note 437 
that zidovudine was not quantified in condition 10xD and diclofenac was stable in condition LSS. The minimal 438 
calculable half-life (3.5 d) is represented by a dotted line. 439 
  440 
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